Primary care clinic

Inclusion Criteria:

• Be male or female from 10 to 18 years of age, inclusive, with open epiphyses
• Have GH deficiency diagnosed by treating pediatric endocrinologist for at least 6 months
• Be undergoing rhGH treatment via self-injection using the Lilly Humatrope® or Pfizer Genotropin® pen injection device for at least 6 months
• Be willing and able to comply with the protocol for the duration of the trial
• Have access to the Internet
• Be able to read, speak and understand English
• If female of childbearing potential, have a negative urine pregnancy test at Screening and use an acceptable form of birth control during the trial, including abstinence, a hormonal contraceptive, intrauterine device, diaphragm with spermicide, or condom with spermicide

Exclusion Criteria:

• Known allergy or hypersensitivity to rhGH or prescribed diluent (0.3% metacresol for click.easy® cartridge)
• Severe illness during the previous 6 months
• Active malignancy (except non-melanomatous skin malignancies)
• Diabetes mellitus (type I or II)
• Pregnancy or lactation
• Any medical condition that, in the opinion of the Investigator, would jeopardize the subject's safety following exposure to the investigational device
• Participation in any other investigational study during the duration of participation in this trial